摘要
炎症性肠病的发生可能和多种细胞因子相关,其中肿瘤坏死因子(TNF)-α信号通路的阻断已作为重要的治疗靶点。阿达木单克隆抗体(ADA)是一种全人源性抗TNF-α单克隆抗体,免疫原性较低,对于英夫利西单克隆抗体治疗失败的炎症性肠病患儿,可考虑使用ADA治疗以获得更好的疗效。
The occurrence of inflammatory bowel disease(IBD)may be related to a variety of cytokines,and the blocking of tumor necrosis factor(TNF)-αsignaling pathway has been an important therapeutic target of IBD.Adalimumab is a fully humanized anti-TNF-αmonoclonal antibody with low immunogenicity.It may be considered for better efficacy in children with IBD who failed infliximab therapy.
作者
王风范
韩亚楠
任晓侠
孙丽娜
姚佳萌
方莹
Wang Fengfan;Han Yanan;Ren Xiaoxia;Sun Lina;Yao Jiameng;Fang Ying(Department of Gastroenterology,Xi′an Children′s Hospital,Xi′an 710003,China)
出处
《中华炎性肠病杂志（中英文）》
2021年第3期267-270,共4页
Chinese Journal of Inflammatory Bowel Diseases
基金
陕西省自然科学基础研究计划资助项目(2020JQ-928)
西安市卫生健康委员会青年培育项目(2020qn14)
西安市儿童医院院级项目-扶持项目(2020C09)。
